CONTER, VALENTINO
 Distribuzione geografica
Continente #
NA - Nord America 3.674
AS - Asia 1.797
EU - Europa 1.614
SA - Sud America 282
AF - Africa 34
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 5
Totale 7.414
Nazione #
US - Stati Uniti d'America 3.600
SG - Singapore 728
CN - Cina 403
IT - Italia 305
RU - Federazione Russa 302
HK - Hong Kong 240
DE - Germania 234
BR - Brasile 225
SE - Svezia 221
VN - Vietnam 211
IE - Irlanda 146
GB - Regno Unito 85
AT - Austria 53
UA - Ucraina 48
CA - Canada 47
FI - Finlandia 46
IN - India 45
FR - Francia 43
TR - Turchia 29
PL - Polonia 28
BD - Bangladesh 26
ID - Indonesia 26
AR - Argentina 25
NL - Olanda 21
DK - Danimarca 19
KR - Corea 18
MX - Messico 17
ZA - Sudafrica 15
SA - Arabia Saudita 14
BE - Belgio 13
ES - Italia 13
IQ - Iraq 12
JP - Giappone 11
EC - Ecuador 9
CO - Colombia 7
EU - Europa 6
GT - Guatemala 6
PE - Perù 6
PT - Portogallo 6
AU - Australia 5
CZ - Repubblica Ceca 5
GR - Grecia 5
CH - Svizzera 4
EG - Egitto 4
PH - Filippine 4
RO - Romania 4
VE - Venezuela 4
KZ - Kazakistan 3
MA - Marocco 3
NO - Norvegia 3
PK - Pakistan 3
PY - Paraguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BG - Bulgaria 2
CY - Cipro 2
IL - Israele 2
IR - Iran 2
JO - Giordania 2
KE - Kenya 2
LB - Libano 2
LT - Lituania 2
NP - Nepal 2
OM - Oman 2
RS - Serbia 2
SN - Senegal 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
AP - ???statistics.table.value.countryCode.AP??? 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BW - Botswana 1
CG - Congo 1
CI - Costa d'Avorio 1
CL - Cile 1
DZ - Algeria 1
GD - Grenada 1
HN - Honduras 1
JM - Giamaica 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LV - Lettonia 1
MU - Mauritius 1
NI - Nicaragua 1
PS - Palestinian Territory 1
SC - Seychelles 1
TH - Thailandia 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
Totale 7.414
Città #
Ann Arbor 677
Singapore 423
Ashburn 398
Fairfield 242
Hong Kong 238
Chandler 219
Wilmington 171
Woodbridge 171
Frankfurt am Main 147
Dublin 145
Houston 144
Seattle 109
New York 101
Cambridge 89
San Jose 89
Dearborn 86
Milan 81
Los Angeles 72
Santa Clara 71
Beijing 65
Hanoi 59
Ho Chi Minh City 52
Princeton 52
Vienna 45
Jacksonville 43
Hefei 33
Nanjing 32
Altamura 28
Shanghai 27
São Paulo 27
Chicago 26
Lawrence 26
Jakarta 23
Warsaw 23
Dallas 22
Helsinki 22
Rome 22
Grafing 20
Moscow 20
London 19
Orem 18
The Dalles 18
Guangzhou 17
Munich 17
Buffalo 16
Denver 16
Dong Ket 15
San Diego 15
Boardman 13
Montreal 13
Poplar 12
Seoul 12
Nanchang 11
Toronto 11
Atlanta 10
Brussels 10
Johannesburg 10
Paris 10
Phoenix 10
Turin 10
Brooklyn 9
Chennai 9
Salt Lake City 9
Tokyo 9
Turku 9
Council Bluffs 8
Kunming 8
Lissone 8
Stockholm 8
Sulmona 8
Andover 7
Ankara 7
Belo Horizonte 7
Da Nang 7
Dhaka 7
Jeddah 7
Mountain View 7
Mumbai 7
Nuremberg 7
Perugia 7
Shenyang 7
Bologna 6
Changsha 6
Haiphong 6
Istanbul 6
Lachine 6
Naples 6
Ottawa 6
Rio de Janeiro 6
Tianjin 6
Amsterdam 5
Baghdad 5
Bonndorf 5
Brasília 5
Edmonton 5
Hangzhou 5
Lappeenranta 5
Lisbon 5
Mexico City 5
Monza 5
Totale 4.889
Nome #
Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies 395
Oral nutritional supplementation in children treated for cancer in low- and middle-income countries is feasible and effective: The experience of the children's hospital manuel de jesus rivera "la mascota" in Nicaragua 327
Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study 323
Reduced-Intensity delayed intensification in standard-Risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: Results of an international randomized trial (AIEOP-BFM ALL 2000) 306
Autologous Purified Peripheral Blood Stem Cell Transplantation Compare to Chemotherapy in Childhood Acute Lymphoblastic Leukemia after Low-Risk Relapse 281
Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: An international collaborative study 280
Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati 280
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations 269
Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: High white blood cell count at diagnosis is the strongest prognostic factor 267
Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants 263
CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia 260
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial 254
The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results 251
Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL 244
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120 236
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000 230
Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? 228
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols 219
Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial 218
Eight-year national multicenter experience on the use of glucarpidase as effective rescue therapy for delayed methotrexate elimination after high-dose methotrexate cycles administered in children with hemato-oncological diseases 216
Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia 210
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis 202
Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10–14 years as compared with those aged 15–17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study 197
Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study 194
Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia 187
The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols 183
Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort 178
A Hematopoietic Stem Cell Transplantation Startup in Iraqi Kurdistan: Results in Thalassemia Patients and Analysis of the Methodology 177
FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD) 157
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease 154
Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia 153
Bone Marrow Stromal Cell Regeneration Profile in Treated B-Cell Precursor Acute Lymphoblastic Leukemia Patients: Association with MRD Status and Patient Outcome 133
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia 122
Totale 7.594
Categoria #
all - tutte 25.986
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.986


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021426 0 0 0 0 0 0 75 89 61 53 68 80
2021/2022484 51 55 66 44 23 52 15 23 35 20 42 58
2022/2023867 88 262 50 85 46 132 15 77 53 2 47 10
2023/2024516 26 16 24 60 64 129 107 26 13 6 5 40
2024/20251.410 56 158 98 80 127 46 63 29 170 206 127 250
2025/20262.024 429 129 215 436 449 167 199 0 0 0 0 0
Totale 7.594